Rosuvastatin for Tocilizumab, an Interleukin-6 Receptor Antibody-induced Dyslipidemia in a Diabetic Patient Complicated With Rheumatoid Arthritis

Hidekatsu Yanai\textsuperscript{a,b,c}, Hiroshi Kaneko\textsuperscript{d}, Yuji Hirowarari\textsuperscript{d}

Abstract

Tocilizumab, which blocks interleukin-6 binding to interleukin-6 receptor, is now approved for the treatment of rheumatoid arthritis (RA). Hyperlipidemia has been reported to be one of the most common adverse effects of tocilizumab, however, the underlying mechanisms remain unknown. To understand lipid metabolism precisely, we measured plasma cytokines, small dense low-density lipoprotein (LDL), oxidized LDL and cholesterol level in each lipoprotein fraction using the high-performance liquid chromatography method before and after the tocilizumab treatment, and also studied the effect of rosuvastatin on tocilizumab-induced dyslipidemia in a diabetic patient complicated with RA. We found that rosuvastatin significantly alleviated the tocilizumab-induced dyslipidemia.

Keywords: Diabetes; Interleukin-6; Small dense low-density lipoprotein; Tocilizumab

Case Report

A 74-year-old woman developed RA and type 2 diabetes, in 2002 and 2004, respectively. Her RA has been treated by non-steroidal anti-inflammatory drugs and methotrexate (4mg / week), and her diabetes has been treated by dietary therapy. In 2010, the treatment using tocilizumab for RA was introduced because her RA disease activity increased. Her body weight was 51.9 kg and height 154.0 cm (BMI 21.9 kg/m\textsuperscript{2}). Fasting plasma glucose and HbA\textsubscript{1c} levels were 108 mg/dl and 7.3%, respectively.

After one month of tocilizumab use, serum high-sensitivity C-reactive protein (hs-CRP) significantly decreased and serum adiponectin and interleukin-6 increased (Fig. 1). HbA\textsubscript{1c} level decreased from 7.3 to 6.8%. Serum levels of total cholesterol (TC) and high-density lipoprotein cholesterol (HDLC) slightly increased, and LDL-C level decreased, and serum triglyceride (TG) levels significantly increased after the tocilizumab treatment (Fig. 2). In the HPLC study, very low-density lipoprotein cholesterol (VLDLC) significantly increased and HDLC decreased (Fig. 3). The sd-LDL and ox-LDL levels were increased (Fig. 4). After two weeks of rosuvastatin use, serum levels of LDL-C, intermediate low-density lipoprotein (IDL-C), VLDL-C, chylomicron (CM)-C, sd-LDL and ox-LDL were significantly decreased, and HDLC remarkably increased (Fig. 3, 4).
Figure 1. Effects of tocilizumab and rosuvastatin on serum interleukin (IL)-6 (A), high-sensitivity C-reactive protein (hs-CRP) (B) and adiponectin (C). a, before the tocilizumab treatment; b, one month after the tocilizumab treatment and before the rosuvastatin use; c, two weeks after the rosuvastatin use.

Figure 2. Effects of tocilizumab and rosuvastatin on serum total cholesterol (TC) (A), triglyceride (TG) (B), low-density lipoprotein-cholesterol (LDL-C) (C) and high-density lipoprotein-cholesterol (HDL-C) (D). a, before the tocilizumab treatment; b, one month after the tocilizumab treatment and before the rosuvastatin use; c, two weeks after the rosuvastatin use.
Figure 3. Effects of tocilizumab and rosuvastatin on serum low-density lipoprotein-cholesterol (LDL-C) (A), very low-density lipoprotein-cholesterol (VLDL-C) (B), intermediate-density lipoprotein-cholesterol (IDL-C) (C), chylomicron-cholesterol (CM-C) (D) and high-density lipoprotein-cholesterol (HDL-C) (E), determined by the high-performance liquid chromatography method. a, before the tocilizumab treatment; b, one month after the tocilizumab treatment and before the rosuvastatin use; c, two weeks after the rosuvastatin use.

Figure 4. Effects of tocilizumab and rosuvastatin on serum oxidized low-density lipoprotein (ox-LDL) (A) and small dense low-density lipoprotein (sd-LDL) (B). a, before the tocilizumab treatment; b, one month after the tocilizumab treatment and before the rosuvastatin use; c, two weeks after the rosuvastatin use.
Discussion

Tocilizumab, which blocks IL-6 binding to IL-6 receptor, is now approved for the treatment of RA [1-3]. In the systematic review of MEDLINE (1998 - June 2008) and International Pharmaceutical Abstracts (1970 - June 2008), hyperlipidemia has been reported to be one of the most common adverse effects of tocilizumab [2]. In another systematic review including eight randomized controlled trial with 3,334 participants, 2,233 treated with tocilizumab and 1,101 controls, significant increases in TC, HDL-C, LDL-C and TG were observed in the tocilizumab treated patients [3]. However, the underlying mechanisms for tocilizumab-induced hyperlipidemia remain unknown.

Tocilizumab decreased hs-CRP and increased adiponectin in our patient, which is favorable for serum lipid metabolism [5, 6], however, tocilizumab remarkably increased TG-rich lipoprotein such as VLDL and atherogenic lipoproteins such as sd-LDL and ox-LDL, and decreased HDL. In our study, serum IL-6 level was increased after the tocilizumab treatment due to the blockade of interleukin-6 receptor. IL-6 is a cytokine that appears to act as an important systematic regulatory hormone in response to inflammation. Serum IL-6 has been reported to increase in RA patients and to be associated with disease activity of RA [7]. Plasma levels of IL-6 correlate positively with insulin resistance and plasma free fatty acids (FFA) levels [8, 9]. Administration of IL-6 to humans induces elevation of plasma FFA and increased plasma FFA appearance, consistent with increased adipocyte lipolysis of TG [10, 11]. IL-6 has been also reported to suppress lipoprotein lipase activity in adipose tissue [12]. Tocilizumab-induced elevation in TG-rich lipoproteins and reduction of HDL may be due to an increased activity of hormone-sensitive lipase and a decreased activity of lipoprotein lipase due to increased serum IL-6 levels by the IL-6 receptor blockade.

Recently, Verges B, et al. reported that rosuvastatin not only induces a significant increase of LDL catabolism, but also has favorable effects on the catabolism of TG-rich lipoproteins, e.g. a significant increase in the catabolism of VLDL and IDL, and a reduction in the production rate of VLDL in type 2 diabetic patients [13]. In our study, rosuvastatin significantly decreased VLDL-C and IDL-C as well as LDL-C, suggesting the effects of rosuvastatin on the metabolism of TG-rich lipoproteins may be beneficial for the tocilizumab-induced dyslipidemia in type 2 diabetic patient. Our study also showed that rosuvastatin increases HDL-C which was reduced by tocilizumab.

Rosuvastatin has been reported to decrease sd-LDL and ox-LDL [14, 15]. Rosuvastatin significantly decreased these elevated atherogenic lipoproteins after the tocilizumab treatment in our patient, which also supports the usefulness of rosuvastatin for tocilizumab-induced dyslipidemia.

Conclusion

Rosuvastatin significantly ameliorated the tocilizumab-induced dyslipidemia. To confirm our findings, further studies, preferably with larger numbers of subjects, will be needed.

Acknowledgments

This work was supported by the Grant of National Center for Global Health and Medicine (22-120).

Consent

Written informed consent was obtained from a patient for publication of this case report.

Authors’ Contributions

All authors were involved in study design, drafting the manuscript and read and approved the final manuscript.

Competing Interests

The authors declare that they have no competing interests.

References


